The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat Topic 10/01/2020: Crazy year, crazy progress–#lungcancer at #ESMO20
- #LCSM Chat Topic 9/3/2020: Is #Cancer Advocacy for Everyone?
- #LCSM Chat Topic 8/6/2020: Update on #COVID19 and #LungCancer
- #LCSM Chat Topic 6/4/2020: #ASCO20 Roundup for #LungCancer
- #LCSM Chat Topic 5/7/2020: #COVID19 testing and #lungcancer: Where we stand today
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials COVID-19; antigen test Drugs EGFR epatients immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day